Mechanism and consequences of RAF kinase activation by small-molecule inhibitors
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Mechanism and consequences of RAF kinase activation by small-molecule inhibitors
Authors
Keywords
-
Journal
BRITISH JOURNAL OF CANCER
Volume 111, Issue 4, Pages 640-645
Publisher
Springer Nature America, Inc
Online
2014-03-19
DOI
10.1038/bjc.2014.139
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients
- (2013) L. Boussemart et al. ANNALS OF ONCOLOGY
- Mutation landscape in melanoma patients clinical implications of heterogeneity of BRAF mutations
- (2013) L Heinzerling et al. BRITISH JOURNAL OF CANCER
- RAF Inhibitors Activate the MAPK Pathway by Relieving Inhibitory Autophosphorylation
- (2013) Matthew Holderfield et al. CANCER CELL
- Enhanced Inhibition of ERK Signaling by a Novel Allosteric MEK Inhibitor, CH5126766, That Suppresses Feedback Reactivation of RAF Activity
- (2013) Nobuya Ishii et al. CANCER RESEARCH
- Allosteric Activation of Functionally Asymmetric RAF Kinase Dimers
- (2013) Jiancheng Hu et al. CELL
- Phase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (GSK2118436) in Patients With Metastatic Melanoma
- (2013) Paolo A. Ascierto et al. JOURNAL OF CLINICAL ONCOLOGY
- Selective RAF inhibitor impairs ERK1/2 phosphorylation and growth in mutant NRAS, vemurafenib-resistant melanoma cells
- (2013) Kaitlyn Le et al. Pigment Cell & Melanoma Research
- Paradoxical oncogenesis: are all BRAF inhibitors equal?
- (2013) Alexander M. Menzies et al. Pigment Cell & Melanoma Research
- BRAF inhibitors suppress apoptosis through off-target inhibition of JNK signaling
- (2013) Harina Vin et al. eLife
- Relief of Profound Feedback Inhibition of Mitogenic Signaling by RAF Inhibitors Attenuates Their Activity in BRAFV600E Melanomas
- (2012) Piro Lito et al. CANCER CELL
- Atypical Melanocytic Proliferations and New Primary Melanomas in Patients With Advanced Melanoma Undergoing SelectiveBRAFInhibition
- (2012) Lisa Zimmer et al. JOURNAL OF CLINICAL ONCOLOGY
- Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
- (2012) Axel Hauschild et al. LANCET
- Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial
- (2012) Georgina V Long et al. LANCET ONCOLOGY
- Progression of RAS-Mutant Leukemia during RAF Inhibitor Treatment
- (2012) Margaret K. Callahan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
- (2012) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- RASMutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors
- (2012) Fei Su et al. NEW ENGLAND JOURNAL OF MEDICINE
- RAF Inhibitor-Induced KSR1/B-RAF Binding and Its Effects on ERK Cascade Signaling
- (2011) Melissa M. McKay et al. CURRENT BIOLOGY
- RASMutations Are Associated With the Development of Cutaneous Squamous Cell Tumors in Patients Treated With RAF Inhibitors
- (2011) Patrick A. Oberholzer et al. JOURNAL OF CLINICAL ONCOLOGY
- RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
- (2011) Poulikos I. Poulikakos et al. NATURE
- Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
- (2010) Sonja J. Heidorn et al. CELL
- Recent Advances in the Research and Development of B-Raf Inhibitors
- (2010) Hui-Fang Li et al. CURRENT MEDICINAL CHEMISTRY
- RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
- (2010) Poulikos I. Poulikakos et al. NATURE
- RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
- (2010) Georgia Hatzivassiliou et al. NATURE
- Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
- (2010) Ramin Nazarian et al. NATURE
- Impact of Feedback Phosphorylation and Raf Heterodimerization on Normal and Mutant B-Raf Signaling
- (2009) D. A. Ritt et al. MOLECULAR AND CELLULAR BIOLOGY
- A dimerization-dependent mechanism drives RAF catalytic activation
- (2009) Thanashan Rajakulendran et al. NATURE
- V600EBRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway
- (2009) C. A. Pratilas et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started